Independent reporting and analysis across technology, science, startups and invention.
The multi-year agreement gives Amazon broader access to application-optimized silicon blueprints while shifting Synopsys toward a license-plus-royalty model. It is a major test of how reusable chip IP will shape the custom-silicon race.
Read story
The 33-megawatt unit in Utah reached contractual commercial operation after a 23-month build, moving enhanced geothermal from small demonstrations toward repeatable utility-scale deployment.
Read story
Google's new frontier model is entering a controlled rollout to trusted cyber defenders before developers or consumers. Its capabilities are ambitious, but public evidence remains dominated by vendor benchmarks and internal deployments.
Read story
Hertha Metals plans a 10,000-tonne plant for the high-purity iron used in rare-earth permanent magnets. A $65 million U.S. government equity investment makes the project an unusually direct industrial-policy bet, but commercial qualification and scale-up remain ahead.
Read story
Dots extend ChatGPT from a session-based assistant into a persistent cloud agent that can work across projects, browsers and connected apps. The launch is consequential, but its safeguards and real-world reliability still need independent evidence.
Read story
The first U.S. appellate result in an AI-training copyright dispute leaves Ross Intelligence's fair-use defense rejected, but the sealed opinion makes sweeping conclusions premature.
Read story
Major technology companies have signed a nonbinding safety framework as a new executive order tells U.S. agencies to replace ‘artificial intelligence’ with ‘super intelligence.’ The two moves signal political urgency, but neither creates an enforceable technical standard.
Read story
The all-stock acquisition would bring Fei-Fei Li and World Labs’ 3D world-model research inside AMD. The strategic logic reaches beyond one product, but closing still requires regulatory approval and commercial payoff remains unproven.
Read story
A Delaware judge refused to dismiss Bayer and Monsanto’s patent suits against Moderna, Pfizer and BioNTech. The ruling keeps the cases alive, but does not establish infringement or finally settle the patent’s validity.
Read story